LYEL · Lyell Immunopharma, Inc.

Track LYEL — free

$8.71 -0.08 (-0.91%)

Russell 2000 member Rebalance outlook locked

Market Cap

$215.40M

24.51M

Volume · Oct 9 106.81K Avg daily vol (3M) 145.6K

Up next

Next earnings call

Oct 19, 2026 Est · unconfirmed · in 1 wks

Latest filing: 10-Q

filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$27,000

Trailing 12 months

Net income (TTM)

−$248.48M

Trailing 12 months

Revenue growth YoY

-50.0%

Year over year

Operating margin

-949,981.5%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-62.2%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$204.10M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+57.9%

Year over year · more shares

Price change (1Y)

-51.9%

Trailing year

Short interest

5.2%

Latest settlement · 7.4 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Strong Sell

SellHoldBuy

Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High

Market backdrop VIX 15.4 · calm Equity put/call 0.62

Technical

price trend

Strong Sell

50 / 200-day cross No cross

Price vs 200-day avg −52%

below

Price vs 50-day avg −30%

below

RSI (14) 25

oversold

MACD trend Negative

52-week position 1%

near low

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −28%

trailing

6-month return −63%

trailing

YTD return −71%

this year

Relative strength −72%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $13 › 200d $18 — 200d above 50d

Institutional flow Accumulating

2 of 88 funds reported for Sep 30 · net +462 sh shares · +1 new

Insider flow Distributing

Net -$211.0K over 90 days · 100% sells

Short interest Rising

5.16% of float · ▲ +6.4% MoM · 7.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

88 holders — mid 3-yr range

Squeeze score 56

elevated · 0–100

Fundamentals

Weak

Revenue growth −41%

Y/Y

EPS growth +39%

Y/Y

Free cash flow $-150.8M

Quant / Vol

risk profile

Very High

Volatility 80%

annualized · 1-yr

Max drawdown −78%

past year

ATR 7.5%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell

4 · 3 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−52% Bearish

Price vs 50-day avg

−30% Bearish

RSI (14)

25 Neutral

MACD trend

Negative Bearish

52-week position

1% Bearish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bearish · 2 of 6

Trend (MA cross) No cross

50d $13 › 200d $18 — 200d above 50d

Institutional flow Accumulating

2 of 88 funds reported for Sep 30 · net +462 sh shares · +1 new

Insider flow Distributing

Net -$211.0K over 90 days · 100% sells

Short interest Rising

5.16% of float · ▲ +6.4% MoM · 7.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

88 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $9 Now $9 · 1% Range high $39

vs 200-day avg -52% vs 50-day avg -30%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
LYEL Lyell Immunopharma, Inc. this stock	$215.40M	-71.4%	-41.0%	—	5.2%
VRTX Vertex Pharmaceuticals Inc / Ma	$127.55B	+11.0%	+46.2%	29.3	1.8%
MRNA Moderna, Inc.	$78.65B	+568.0%	+4.3%	—	7.7%
REGN Regeneron Pharmaceuticals, Inc.	$76.14B	-4.2%	+20.8%	18.3	2.1%
CSLLY Csl Ltd	$61.58B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

% held: 52.0%
Reported: 2 of 88
Top holder: ARCH Venture Management,…

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Rising

Shares short

1.3M

Days to cover: 7.4d
Change: +75.5K sh

View

Short Volume

Short vol %

51%

As of: Oct 9, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $232
As of: Sep 10, 2026

View

Off-Exchange

Off-exchange %

35.6%

Week of: Aug 31, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$211.0K

Buyers / Sellers: 0 / 5

Buyers Sellers

View

Financials

Revenue (FY)

$36.0K

Net income (FY): $-274.4M
EPS diluted: $-16.06

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Sep 15, 2026
This year: 12

View

Proposed Sales

Value

$10.3K

Shares: 4.5K
Filed: Aug 15, 2023

View

Exempt Offerings

Offering

$493.0M

Filed: Mar 20, 2020

View

Earnings & Events

Webcasts

Last webcast

Sep 15, 2026

View

Performance

	5D	20D	120D	MTD	YTD
LYEL	-6.6%	-28.0%	-63.4%	-10.2%	-71.4%
SPY	+1.3%	+2.1%	+9.0%	+1.5%	+13.5%
vs SPY	-7.9%	-30.1%	-72.4%	-11.7%	-84.9%

Key facts CIK 1806952 CUSIP 55083R203 13F (30d) 3 filings 3 filers Visit website Investor relations

LYEL · Lyell Immunopharma, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance